Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > LATEST
LATEST
-
REGULATORY Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
-
REGULATORY PMDA Reviewing New Safety Risks for Itraconazole, I/O Drugs and More
September 12, 2022
-
REGULATORY PMDA Sets 1st “GMP Roundtable” with Academia, Industry in November
September 12, 2022
-
REGULATORY Japan to End Govt-Controlled Supply of Lagevrio on Sept. 15: MHLW
September 12, 2022
-
COMMENTARY Generic Industry Has High Hopes on New Expert Panel; Will Its Recommendations Ease Impact of Annual Re-Pricing?
September 9, 2022
-
REGULATORY Japan to Boost Number of HPV Vaccination Base Hospitals
September 9, 2022
-
REGULATORY What Is Seen as New Omicron Variant Detected in Japan: NIID
September 9, 2022
-
ACADEMIA Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
-
ORGANIZATION FPMAJ-Eyed Overhaul of Price Revision Rules Likely to Curb Price Falls, Cover JP-Listed Meds, Essential Drugs and More
September 9, 2022
-
ORGANIZATION Rapid Removal of NHI-Market Price Gap Will Cause Chaos: Pharmacy Industry Chief
September 9, 2022
-
BUSINESS Japan’s First CAD Therapy, Enjaymo, Now Available: Sanofi
September 9, 2022
-
BUSINESS Japan Ethical Drug Sales Up 0.8% in July: Crecon
September 9, 2022
-
BUSINESS Lagevrio’s Normal Distribution to Start from Sept. 16: MSD
September 9, 2022
-
ACADEMIA University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
-
REGULATORY Guardians Now Urged to Get Kids Ages 5-11 Vaccinated against COVID-19
September 8, 2022
-
ORGANIZATION JMA President Confirms Need for Profits from NHI-Market Price Gap
September 8, 2022
-
BUSINESS Samsca Generics Get Additional Indication for Heart Failure, AG Too
September 8, 2022
-
REGULATORY LDP Group Urges Thorough Discussions on New Data for Shionogi COVID Pill Once Out
September 8, 2022
-
BUSINESS AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
-
BUSINESS AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…